Aligos Therapeutics Inc stock is traded at $4.07, with a volume of 101,665. It is down -9.76% in the last 24 hours and down -24.35% over the past month. Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Previous Close:
$4.51
Open:
$4.44
24h Volume:
101,665
Relative Volume:
2.96
Market Cap:
$25.42M
Revenue:
$4.71M
Net Income/Loss:
-$90.32M
P/E Ratio:
-
EPS:
-$8.70
Net Cash Flow:
-$85.19M
1W Performance:
-15.21%
1M Performance:
-24.35%
6M Performance:
-36.11%
1Y Performance:
-42.68%
1-Day Range:
$4.00$4.86
1-Week Range:
$4.00$5.14
52-Week Range:
$3.98$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(800) 466-6059Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS